|Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells|
RT Mitsuyasu, TC Merigan, A Carr, JA Zack, MA Winters, C Workman, ...
Nature medicine 15 (3), 285-292, 2009
|Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase|
JM Murray, S Emery, AD Kelleher, M Law, J Chen, DJ Hazuda, ...
Aids 21 (17), 2315-2321, 2007
|Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients|
T Volz, M Lutgehetmann, P Wachtler, A Jacob, A Quaas, JM Murray, ...
Gastroenterology 133 (3), 843-852, 2007
|Kinetics of acute hepatitis B virus infection in humans|
SA Whalley, JM Murray, D Brown, GJM Webster, VC Emery, GM Dusheiko, ...
The Journal of experimental medicine 193 (7), 847-854, 2001
|Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination|
M Markowitz, X Jin, A Hurley, V Simon, B Ramratnam, M Louie, ...
The Journal of infectious diseases 186 (5), 634-643, 2002
|Dynamics of hepatitis B virus clearance in chimpanzees|
JM Murray, SF Wieland, RH Purcell, FV Chisari
Proceedings of the National Academy of Sciences 102 (49), 17780-17785, 2005
|Optimal control for a cancer chemotheraphy problem with general growth and loss functions|
Mathematical Biosciences 98 (2), 273-287, 1990
|Long‐term survival and concomitant gene expression of ribozyme‐transduced CD4+ T‐lymphocytes in HIV‐infected patients|
JL Macpherson, MP Boyd, AJ Arndt, AV Todd, GC Fanning, JA Ely, ...
The Journal of Gene Medicine: A cross‐disciplinary journal for research on …, 2005
|CD4+ T-Cell Deficiency in HIV Patients Responding to Antiretroviral Therapy Is Associated With Increased Expression of Interferon-Stimulated Genes in CD4+ T …|
S Fernandez, S Tanaskovic, K Helbig, R Rajasuriar, M Kramski, ...
The Journal of infectious diseases 204 (12), 1927-1935, 2011
|Some optimal control problems in cancer chemotherapy with a toxicity limit|
Mathematical Biosciences 100 (1), 49-67, 1990
|Naive T cells are maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty|
JM Murray, GR Kaufmann, PD Hodgkin, SR Lewin, AD Kelleher, ...
Immunology and Cell Biology 81 (6), 487-495, 2003
|The half‐life of hepatitis B virions|
JM Murray, RH Purcell, SF Wieland
Hepatology 44 (5), 1117-1121, 2006
|The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users|
JM Murray, MG Law, Z Gao, JM Kaldor
International Journal of Epidemiology 32 (5), 708-714, 2003
|In vivo proliferation of hepadnavirus‐infected hepatocytes induces loss of covalently closed circular DNA in mice|
M Lutgehetmann, T Volz, A Köpke, T Broja, E Tigges, AW Lohse, E Fuchs, ...
Hepatology 52 (1), 16-24, 2010
|HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy|
JM Murray, JJ Zaunders, KL McBride, Y Xu, M Bailey, K Suzuki, ...
Journal of virology 88 (6), 3516-3526, 2014
|Timing of the components of the HIV life cycle in productively infected CD4+ T cells in a population of HIV-infected individuals|
JM Murray, AD Kelleher, DA Cooper
Journal of virology 85 (20), 10798-10805, 2011
|The prevalence of sexually transmitted infections in Papua New Guinea: a systematic review and meta-analysis|
A Vallely, A Page, S Dias, P Siba, T Lupiwa, G Law, J Millan, DP Wilson, ...
PloS one 5 (12), e15586, 2010
|A model of primary HIV-1 infection|
JM Murray, G Kaufmann, AD Kelleher, DA Cooper
Mathematical Biosciences 154 (2), 57-85, 1998
|Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir|
KK Koelsch, C Boesecke, K McBride, L Gelgor, P Fahey, V Natarajan, ...
Aids 25 (17), 2069-2078, 2011
|Optimal control for a stochastic model of cancer chemotherapy|
AJ Coldman, JM Murray
Mathematical biosciences 168 (2), 187-200, 2000